Eli Lilly Earnings Call Signals High-Growth Trajectory

Eli Lilly And Company ((LLY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Eli Lilly’s latest earnings call painted a decidedly upbeat picture, with management leaning into blockbuster growth from its incretin franchise and a sharply upgraded outlook for 2026. Executives acknowledged rising price pressure, heavier spending and patchy access, but argued these are manageable trade-offs against surging demand, a deep late-stage pipeline and strategic deals that position the company for sustained momentum.

Explosive Revenue Growth and Upgraded Outlook

Revenue surged 56% year over year in Q1 2026, prompting Lilly to lift full-year guidance by $2 billion at both ends to a new range of $82 billion to $85 billion. At the midpoint, that implies roughly 28% growth versus 2025, underscoring how rapidly the business is scaling on the back of obesity and diabetes therapies despite mounting headwinds from pricing and access.

Incretin Powerhouse Drives the Top Line

The company’s incretin franchise, led by Mounjaro and Suven, delivered a combined $12.8 billion in Q1 revenue and accounted for $6.7 billion of the year-on-year growth. Management emphasized that key products collectively contributed more than $7 billion in incremental sales, reinforcing the central role these therapies play in Lilly’s growth algorithm and the broader obesity and metabolic opportunity.

Prescription Growth and Global Incretin Momentum

U.S. incretin analog prescriptions climbed more than 80% in the quarter, while international incretin markets expanded 77% year over year based on IQVIA gross sales. Mounjaro’s uptake ex-U.S. has been especially strong, with average market share above 53% and levels near 60% in select countries such as Korea, highlighting its competitive positioning in fast-developing markets.

Record Earnings and Expanding Performance Margins

Non-GAAP EPS more than doubled to $8.55 from $3.34 a year earlier, powered by operating leverage as volumes scaled. Lilly’s non-GAAP performance margin reached 50%, about seven percentage points higher year on year, while gross margin held a lofty 82.6% of revenue despite modest compression, underscoring the profitability of its current product mix.

Foundayo’s U.S. Launch Adds a New Growth Lever

Foundayo, Lilly’s oral GLP-1 for obesity, secured U.S. approval and launched in April, giving the company a convenient pill-based entry into the weight-loss market. Early signals include broad pharmacy stocking by April 9, placement on more than a dozen telehealth platforms, confirmation of access at two of the three largest pharmacy benefit managers and more than 8,000 prescribers treating over 20,000 patients.

Pipeline Wins and Phase III Firepower

Management highlighted a string of positive clinical readouts, including the ACHIEVE I trial showing cardiovascular safety and potential risk reductions for Foundayo and robust Phase II results for retatrutide with meaningful A1c and weight loss benefits. Additional gains in hematology, dermatology and combination regimens support confidence in a pipeline that now features 42 active Phase III programs and multiple new late-stage starts.

Strategic Deals Bolster Future Platforms

Lilly continued to flex its balance sheet in business development, announcing or closing transactions with Orna Therapeutics, Syntessa, Colonia Therapeutics, Ajax Therapeutics, Ventix Biosciences and Contessa Pharmaceuticals. These deals expand capabilities into in vivo CAR-T, sleep-wake disorders, next-generation JAK and NLRP3 inhibitors and orexin receptor agonists, broadening the company’s reach beyond metabolic disease.

Capital Returns and Shareholder Focus

The company balanced aggressive investment with shareholder payouts, distributing $1.5 billion in dividends and repurchasing $2.4 billion of stock in the quarter. At the same time, Lilly increased its full-year non-GAAP EPS guidance to a range of $35.50 to $37 and reiterated that business development will remain disciplined and return-focused, signaling confidence in both internal and external value creation.

Pricing Pressure and Margin Headwinds

Against this bullish backdrop, Lilly acknowledged that U.S. pricing declined about 7% in Q1 and would have been closer to 10% absent a one-time adjustment. Management now expects price to be a low- to mid-teens headwind for the full year, which will weigh on gross margin and net pricing even as volume growth remains strong and the company works to offset pressure with scale.

Rising Investment in Marketing and R&D

To support its expanding portfolio and launches, Lilly ramped operating investments, with marketing, selling and administrative expenses up 19% and R&D spending up 28%. While gross margin slipped by roughly a point to 82.6%, executives framed the heavier spend as necessary to defend share, fuel innovation and advance the unusually large Phase III slate, though they cautioned this could temper near-term margin gains if market dynamics shift.

Access Challenges and Medicaid Setbacks

The company noted that loss of Medicaid coverage in certain U.S. states reduced Q1 prescription growth by the high single digits, highlighting ongoing access friction across payer types. Broader variability in commercial, Medicaid and Medicare coverage remains a drag on uniform uptake, adding another layer of uncertainty even as consumer demand appears robust.

Early Stage and Uncertain Near-Term Foundayo Impact

Despite promising early metrics, management stressed that Foundayo’s launch is in its infancy, with only a few weeks of data available when guidance was raised. Executives declined to quantify how much of the outlook increase stems from the new oral GLP-1, suggesting its near-term revenue contribution remains uncertain even as they see substantial long-term potential.

Competitive and Generic Pressures Build

Lilly flagged the arrival of generic semaglutide in markets such as India, noting that generics have so far expanded the overall category while Mounjaro has held share. Still, management acknowledged that generic competition poses ongoing risks to pricing and market mix, especially as international obesity and diabetes markets mature and payers sharpen their focus on cost.

Reliance on Self-Pay Channels Raises Sensitivity

The company’s growth has leaned heavily on out-of-pocket demand, with roughly three-quarters of historical ex-U.S. Mounjaro sales coming from self-pay customers and U.S. self-pay and digital channels remaining sizeable. That reliance boosts near-term revenue but also heightens sensitivity to affordability, policy changes and future shifts in insurance coverage that could reshape demand.

Upgraded 2026 Guidance and Outlook

Lilly’s updated 2026 guidance calls for revenue of $82 billion to $85 billion and non-GAAP EPS of $35.50 to $37, alongside a non-GAAP performance margin of 47% to 48.5% and an unchanged tax rate. Management said the higher outlook reflects the powerful Q1 showing across Mounjaro, semaglutide biosimilars and other key drugs, while explicitly baking in a low- to mid-teens pricing headwind and ongoing investment in commercial and R&D capabilities.

Lilly’s earnings call underscored a company riding unprecedented demand for its obesity and diabetes therapies while aggressively seeding future growth through pipeline bets and acquisitions. Investors will need to watch how pricing pressure, access constraints and competition evolve, but for now the narrative is one of high growth, strong profitability and a management team willing to spend to stay ahead of a rapidly shifting market.